2025 Financial Outlook
The Company issued its outlook for 2025; summarized below:
- Revenue for 2025 to be in a range of $10.85 billion to $11.15 billion
- Adjusted EBITDA for 2025 to be in a range of $560 million to $590 million
- Adjusted EPS for 2025 to be in a range of $1.60 to $1.85
The Company's outlook for 2025 excludes any impact of the previously announced Rotech acquisition, any potential transaction involving the Products & Healthcare Services segment, or share repurchase activity, and contains assumptions, including current expectations regarding the impact of general economic conditions.
Key assumptions supporting the Company's 2025 financial guidance include:
- Gross margin of 20.75% to 21.25%
- Interest expense of $138 million to $142 million
- Adjusted effective tax rate of 29.0% to 30.0%
- Diluted weighted average shares of ~80 million
- Capital expenditures, gross, of $250 million to $270 million
- Stable commodity prices
- FX rates as of 12/31/2024